VectivBio AG
11
0
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
18%
2 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
Role: lead
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
Role: lead
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Role: lead
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Role: lead
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
Role: lead
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
Role: lead
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
Role: collaborator
Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
Role: lead
Evaluation of Apraglutide on Gastric Emptying
Role: lead
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency
Role: collaborator
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
Role: collaborator
All 11 trials loaded